Loading stock data…
REGN
$712.61-2.29 (-0.32%)
Market OpenUpdated 3:58 PM EDT
Regeneron Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Regeneron Pharmaceuticals, Inc. in the Healthcare sector is trading at $712.44. The stock is currently 13% below its 52-week high of $821.11, remaining 3.7% above its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why REGN maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$712.61
Potential Upside
15.9%
Whystock Fair Value$826.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Buy
Mean target$875.31+22.8%
Range$730.00 – $1057
Fundamentals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$78.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Strong income play. Yield provides a meaningful total return floor.
50.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.26%
Volume
Today's trading volume
695,335
Recent News
Regeneron’s Otarmeni Win Links Gene Therapy Ambition With ESG Commitments
Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Otarmeni, the first gene therapy for genetic hearing loss. The company plans to provide Otarmeni at no cost to eligible patients in the U.S. Regeneron introduced new science led responsibility goals through 2030 and reported fresh ESG accolades. Regeneron enters this news cycle with a current share price of $709.1 and a mixed return profile, including 30.2% over the past year and 38.0% over five years, alongside a 4.2%...
The Nasdaq's top winners are now running hotter than in 2000: Chart of the Day
The top dot-com stocks were making history 2000. Today's Nasdaq winners are crushing those gains.
Is This Biotech Stock a Buy After a Groundbreaking Approval?
This milestone came with an asterisk.
Trump’s Affordability Push Stalls Ahead of Midterm Elections
(Bloomberg) -- The Trump administration’s fitful campaign to address US voters’ affordability concerns ahead of the midterm elections is faltering, with some key efforts stalled, cast aside or limited in scope. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysDOJ Plans Intervention in Trump Supreme Court Carroll AppealBillionaire Duke of Westminster to Sell £700 Million of US Real Estate AssetsChina Asks Banks to Pause New Loans to US-Sanctioned RefinerSony to
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.